Bhatt Kavita V, Spofford Laurie S, Aram Gazelle, McMullen Meghan, Pumiglia Kevin, Aplin Andrew E
Center for Cell Biology and Cancer Research, Albany Medical College, 47 New Scotland Avenue, MC-165, Albany, NY 12208, USA.
Oncogene. 2005 May 12;24(21):3459-71. doi: 10.1038/sj.onc.1208544.
Mutations in BRAF, a component of extracellular signal-regulated kinases 1 and 2 (ERK) cascade, are frequent in melanoma. It is important to understand how BRAF mutations contribute to malignant traits including anchorage- and growth factor-independence. We have previously shown that efficient activation of ERK in normal human epidermal melanocytes (NHEM) requires both adhesion to the extracellular matrix and growth factors. Mutant V599E BRAF is sufficient to promote ERK activation independent of adhesion and growth factors. Here, we analysed regulation of G1 cell cycle events in NHEM and human melanoma cells. We show that S phase entry in NHEM requires both adhesion and growth factor signaling through the MEK-ERK pathway. This control correlates with induction of cyclin D1 and downregulation of p27Kip1, two key G1 cell cycle events. In melanoma cells expressing V599E BRAF, cyclin D1 was constitutively expressed independent of adhesion but dependent upon MEK activation and nuclear accumulation of ERK. Reduction of cyclin D1 levels by RNA interference inhibited S phase entry in melanoma cells. Importantly, expression of V599E BRAF in NHEM was sufficient to promote cyclin D1 promoter activity in the absence of adhesion. Additionally, p27Kip1 levels were downregulated in V599E BRAF-expressing melanoma cells and active BRAF was sufficient to downregulate p27Kip1 in serum-starved NHEM. Thus, adhesion-growth factor cooperation, leading to efficient activation of ERK, regulates cyclin D1 and p27Kip1 levels in human melanocytes and mutant BRAF overrides adhesion-growth factor control of these two G1 cell cycle proteins in melanomas. These findings provide important insight into how BRAF mutations contribute to aberrant human melanocyte proliferation.
BRAF作为细胞外信号调节激酶1和2(ERK)级联反应的一个组成部分,其突变在黑色素瘤中很常见。了解BRAF突变如何导致包括不依赖锚定和生长因子在内的恶性特征非常重要。我们之前已经表明,在正常人表皮黑素细胞(NHEM)中,ERK的有效激活既需要与细胞外基质黏附,也需要生长因子。突变型V599E BRAF足以促进ERK的激活,而不依赖于黏附和生长因子。在这里,我们分析了NHEM和人黑色素瘤细胞中G1细胞周期事件的调控。我们发现,NHEM进入S期既需要通过MEK-ERK途径的黏附信号,也需要生长因子信号。这种调控与细胞周期蛋白D1的诱导和p27Kip1的下调相关,这是G1细胞周期的两个关键事件。在表达V599E BRAF的黑色素瘤细胞中,细胞周期蛋白D1组成性表达,不依赖于黏附,但依赖于MEK激活和ERK的核积累。通过RNA干扰降低细胞周期蛋白D1的水平可抑制黑色素瘤细胞进入S期。重要的是,在没有黏附的情况下,NHEM中V599E BRAF的表达足以促进细胞周期蛋白D1启动子的活性。此外,在表达V599E BRAF的黑色素瘤细胞中p27Kip1水平下调,活性BRAF足以在血清饥饿的NHEM中下调p27Kip1。因此,黏附-生长因子协同作用导致ERK的有效激活,调节人黑素细胞中细胞周期蛋白D1和p27Kip1的水平,而突变型BRAF在黑色素瘤中则超越了黏附-生长因子对这两种G1细胞周期蛋白的控制。这些发现为BRAF突变如何导致异常的人黑素细胞增殖提供了重要的见解。